Southern California-based General Cannabis, Inc. (OTCPK: CANA) was the focus of an extended analytical report by NBT Equities Research, an independent equities research organization focused on discovering the largest, fastest growing emerging secular growth sectors. General Cannabis has been identified as an interest to the group, who anticipate that the company will generate $60 million-plus in revenue by next year.
General Cannabis is the dominant medicinal MSO in the United States and is primed to solidify their industry domination even further following the completion of a $20 million infusion of equity funding scheduled for later this spring. Medicinal Cannabis is estimated to be between a $35 billion and $45 billion industry and General Cannabis, through their technology and data-driven business strategy, has emerged at its forefront through the employment of various technological platforms, search engine optimization (SEO) strategies, and proprietary software applications designed revolutionize the medicinal marijuana market.
NBT Equities Research expects that CANA will grow to a $1 billion market valuation by 2014, according to the report.
“We expect that General Cannabis Inc. will up-list its common stock listing to a full national Nasdaq listing and inclusion within multiple Russell indexes and popular retail indexes,” Tobin Smith, founder and Chief Research Analyst for NBT Equities Research, states in the report.
“Literally every dispensary open or opening requires a host of one-time and ongoing professional and marketing services. Every medically approved patient has numerous recommendation, availability, quality, and ancillary product questions and issues.
Hundreds of new dispensaries open quarterly nationwide, and tens of thousands of new patients are registered every month. The rate of growth of those key metrics is expected to rise over the next 12-24 months as major population states come online with new dispensaries and registered patients.”
General Cannabis, through servicing ancillary markets of the medicinal cannabis industry will directly benefit from this growth.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer